Peptide Purity Testing Explained: What the Lab Results Actually Tell You

The peptide market is unregulated. Anyone can bottle a powder, print a label, and list it online. Most vendors offer a "Certificate of Analysis" — but that piece of paper is only as reliable as the lab that produced it, and often the lab is chosen by the vendor, not by you.

A peptide purity test is the only way to independently verify what's actually inside the vial. This guide explains what the test actually does, what the numbers mean, and what they don't tell you — so you can make an informed decision before using anything.

What is a peptide purity test?

A peptide purity test is a laboratory analysis that confirms two things: the identity of the compound in a sample and the percentage of that sample made up by the target compound. The standard method used in pharmaceutical and research settings is HPLC — High-Performance Liquid Chromatography — which separates components in a solution and measures each one's concentration relative to the whole.

In practice, you send a sample of your peptide to an independent lab. The lab runs it through the HPLC system, produces a chromatogram — a visual graph showing each compound detected — and reports back a purity percentage. If you ordered BPC-157 and the lab identifies BPC-157 at 97.4% purity, that's what the test tells you.

What it doesn't tell you is covered further down. There are real limits to what HPLC can detect — understanding those limits matters just as much as the headline number.

What HPLC analysis actually measures

HPLC works by pushing a dissolved sample through a column filled with material that interacts differently with different compounds. Each compound moves through the column at a different speed depending on its chemical properties. A detector at the end of the column records what arrives and when.

The result is a chromatogram: a series of peaks, each representing a distinct compound. The largest peak is typically the target peptide. The area under each peak, expressed as a percentage of total peak area, gives you the purity reading.

What this shows you specifically:

• Compound identity — The time at which a compound passes through the column (its "retention time") is compared against a known reference standard. If your sample's main peak matches the known retention time for BPC-157, the compound identity is confirmed.
• Purity percentage — The area of the target compound's peak divided by the total area of all peaks detected. A 98% reading means 98% of everything detected is the target compound.
• Impurity profile — The smaller peaks on the chromatogram show what else is present. A complete lab report shows these secondary peaks, not just the headline purity number.

Mass spectrometry (MS) is sometimes run alongside HPLC to confirm molecular weight — adding a second layer of identity verification. This combination, HPLC-MS, is the gold standard for peptide analysis in both pharmaceutical and research contexts.

What does a purity percentage actually mean?

A purity percentage tells you what fraction of the detected material is your target compound. A result of 98% means that for every 100 units the instrument detected, 98 were identified as the target peptide and 2 were something else. What that "something else" is — that's the part the headline number doesn't tell you.

The 98% benchmark — is it actually enough?

Pharmaceutical-grade peptides used in clinical settings typically require ≥98% purity. Research-grade peptides sold for laboratory use often target 95%+. The grey-market consumer space varies widely: 90%, 95%, 98%, and occasionally higher.

Whether 98% is "enough" depends on the compound, the dose, and the individual. A 2% impurity load on a 1mg dose is 20 micrograms of unknown material. On a 10mg dose, that's 200 micrograms. For most peptides at typical doses this is unlikely to be significant — but "unlikely" is doing a lot of work when you don't know what that 2% actually is.

What makes up the remaining percentage?

This is the question the headline number doesn't answer. The remaining fraction typically consists of one or more of the following:

• Synthesis byproducts — Incomplete sequences, deletion peptides (fragments missing one amino acid), or truncated variants. These are common in peptide synthesis and usually inert at trace levels.
• Oxidised variants — Peptides degrade when exposed to oxygen, heat, or moisture. Methionine residues are particularly susceptible. An oxidised peptide may have significantly altered bioactivity compared to the intact compound.
• Reagent residues — Synthesis relies on chemical reagents that must be thoroughly removed during purification. Incomplete purification leaves residues that appear on the chromatogram.
• A different compound entirely — In cases of deliberate substitution or severe quality failures, the main peak may not match the target at all. This is rare but documented in independent testing of the grey market.

The impurity profile — the full breakdown of what those secondary peaks actually represent — is the most informative part of a lab report. It's also the part most vendors don't share, and that most buyers never think to ask for.

Why the peptide market has a quality problem

Peptides sold for human use exist in a legal grey zone across most of Europe. They are not classified as medicines, not regulated as food supplements, and there is no enforcement body checking purity, labelling accuracy, or manufacturing standards. The barrier to entering this market is effectively zero.

This creates a predictable outcome. The market contains vendors ranging from careful, quality-focused operations with genuine laboratory relationships, to those whose products have never been independently analysed. From the outside, there's often no reliable way to tell them apart — the websites look similar, the product descriptions use the same language, and certificates of analysis are straightforward to produce.

The vendor's own Certificate of Analysis is not a reliable differentiator. Certificates can be outdated (from a batch that has since changed), produced by a lab with a commercial relationship to the vendor, or in some cases, not representative of what you actually received. An independent test — ordered by you, submitted to a lab with no relationship to the vendor — removes that uncertainty.

Our peptide testing service runs all samples through Analiza Białek in Poland, a fully accredited analytical laboratory with no commercial relationship with any peptide vendor. The result you receive reflects the compound in your specific submission.

What a purity test can — and can't — catch

Understanding the limits of HPLC matters as much as understanding what it confirms. Knowing what the test misses helps you decide whether additional analysis is worth considering.

What a standard HPLC purity test can identify:

• A wrong compound — if the main peak's retention time doesn't match the target
• Low purity — elevated levels of synthesis byproducts or degradation products
• A missing compound — a vial that contains little or none of the stated peptide
• Significant contamination — large secondary peaks indicating substantial foreign material

What HPLC alone typically cannot detect:

• Bacterial endotoxins (pyrogens) — Fragments of bacterial cell walls that can trigger serious inflammatory responses. These are not organic compounds in the conventional HPLC sense — detecting them requires a separate LAL (Limulus Amebocyte Lysate) test. For anyone injecting a peptide, even subcutaneously, this is a relevant consideration.
• Microbial contamination — Whether a vial contains live bacteria or fungi cannot be determined from a chromatogram. Sterility testing requires microbiological culture methods.
• Trace heavy metals — Some manufacturing processes introduce trace metals. Detecting these requires ICP-MS or comparable techniques, not HPLC.

This is why supplementary add-on tests exist as a separate analysis option. An endotoxin test specifically checks for pyrogen contamination that a standard purity analysis would miss entirely. If you're planning subcutaneous or intramuscular administration, it's worth knowing this test exists.

Third-party vs. the seller's own certificate

Is there a meaningful difference between a vendor-provided Certificate of Analysis and an independent third-party test? Yes — and it comes down to incentives.

A vendor-provided certificate is produced by a lab the vendor chose, hired, and may have a long-term commercial relationship with. The vendor also controls which batches get tested and which results get published. Even with the best intentions, this structure creates conflicts of interest that are difficult to eliminate entirely.

An independent third-party test is initiated by you, using a sample you select, submitted to a lab you choose, with results reported directly to you. The lab has no commercial relationship with the vendor and no incentive to produce any particular outcome.

A vendor's certificate tells you what they want you to know. A third-party result tells you what was actually in your sample on the day it was tested. For a compound you intend to inject, that distinction is not minor.

Before you inject: the practical takeaway

The peptide market isn't going to self-regulate. The absence of regulatory oversight means quality variance is a structural feature, not a temporary problem.

A peptide purity test won't answer every question — sterility, endotoxins, and heavy metals each require separate analysis. But it will tell you whether the compound in your vial is what it claims to be and whether the purity falls within a reasonable range. For most people, that's the first question that needs answering.

Whether you're using BPC-157 for tissue repair or Semaglutide for metabolic support, an independent lab report is the closest thing to certainty available in this market. Not a guarantee — but evidence. Something you can look at, verify against a reference standard, and make a genuine decision from.

That's what a purity test actually gives you.